<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-HGFZXIGI</identifier><date>2019</date><creator>Świerczyński, Marek</creator><creator>Więckowski, Zbigniew</creator><relation>documents/doc/H/URN_NBN_SI_doc-HGFZXIGI_001.pdf</relation><relation>documents/doc/H/URN_NBN_SI_doc-HGFZXIGI_001.txt</relation><format format_type="volume">12</format><format format_type="type">article</format><format format_type="issue">iss. 2</format><format format_type="extent">str. 21-38</format><identifier identifier_type="DOI">10.18690/mls.12.2.21-38.2019</identifier><identifier identifier_type="ISSN">2463-7955</identifier><identifier identifier_type="COBISSID">43517443</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-HGFZXIGI</identifier><language>eng</language><publisher publisher_location="Maribor">Pravna fakulteta</publisher><source>Medicine, law &amp; society</source><rights>BY</rights><subject language_type_id="slv">biologic medicinal product</subject><subject language_type_id="slv">biološka zdravila</subject><subject language_type_id="slv">biopharmaceuticals</subject><subject language_type_id="slv">farmacija</subject><subject language_type_id="slv">innovation</subject><subject language_type_id="slv">intelektualna lastnina</subject><subject language_type_id="slv">intellectual property</subject><subject language_type_id="slv">IP exclusive rights</subject><subject language_type_id="slv">patenti</subject><title>Biosimilars and the patent law</title></Record>